Company profile for HiberCell

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Decades of therapeutic and diagnostic improvements have provided considerable benefit to cancer patients battling their primary tumors. Unfortunately, those battling relapse and metastasis have not benefited as much from these advancements and they now account for the vast majority of cancer-related deaths. To this day, there are limited treatment options in this setting. At HiberCell, we are focused on developing novel ther...
Decades of therapeutic and diagnostic improvements have provided considerable benefit to cancer patients battling their primary tumors. Unfortunately, those battling relapse and metastasis have not benefited as much from these advancements and they now account for the vast majority of cancer-related deaths. To this day, there are limited treatment options in this setting. At HiberCell, we are focused on developing novel therapeutics to overcome foundational barriers that prevent patients from living longer, cancer-free lives.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2825 Fairview Avenue N, Roseville, MN 55113
Telephone
Telephone
651.675.0300
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-and-hibercell-enter-into-an-exclusive-development-and-option-agreement-for-first-in-human-compound-302603732.html

PR NEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/05/27/3088667/0/en/HiberCell-Announces-Successful-Completion-of-Dose-Escalation-and-Enrollment-Update-for-Ph1b-Study-Evaluating-HC-7366-in-Combination-with-WELIREG-belzutifan-in-Advanced-ccRCC.html

GLOBENEWSWIRE
27 May 2025

https://www.globenewswire.com/news-release/2024/10/23/2967964/0/en/HiberCell-Receives-FDA-Fast-Track-Designation-for-HC-7366-for-the-Treatment-of-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-AML.html

GLOBENEWSWIRE
23 Oct 2024

https://www.globenewswire.com/news-release/2024/05/28/2888943/0/en/HiberCell-Announces-First-Patient-Dosed-in-Phase-1b-Clinical-Trial-Evaluating-HC-7366-in-Combination-with-Venetoclax-and-Azacitidine-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML.html

GLOBENEWSWIRE
28 May 2024

https://www.globenewswire.com/news-release/2024/05/01/2873708/0/en/HiberCell-Announces-First-Patient-Dosed-in-Clinical-Collaboration-with-Merck-Evaluating-HC-7366-in-Combination-with-WELIREG-belzutifan-in-patients-with-advanced-ccRCC.html

GLOBENEWSWIRE
01 May 2024

https://www.globenewswire.com/news-release/2024/04/05/2858583/0/en/HiberCell-Announces-Recent-Publication-and-Poster-Presentations-for-its-Novel-GCN2-Activator-HC-7366.html

GLOBENEWSWIRE
05 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty